Coumermycin A(1) | 4434-05-3

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: Coumermycin A(1)
• 英文别名: Notomycin；[5-hydroxy-6-[4-hydroxy-3-[[5-[[4-hydroxy-7-[3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1H-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]carbamoyl]-4-methyl-1H-pyrrole-3-carbonyl]amino]-8-methyl-2-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] 5-methyl-1H-pyrrole-2-carboxylate
• CAS: 4434-05-3
• 化学式: C₅₅H₅₉N₅O₂₀
• 分子量: 1110.09
• InChiKey: WTIJXIZOODAMJT-UHFFFAOYSA-N

物化性质

• 熔点：
  259°C (rough estimate)
• 沸点：
  821.5°C (rough estimate)
• 密度：
  1.1866 (rough estimate)
• 溶解度：
  在DMSO中的溶解度为50 mg/mL，清澈，淡黄色

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  80
• 可旋转键数：
  16
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  347
• 氢给体数：
  9
• 氢受体数：
  20

安全信息

• 安全说明：
  S36
• 危险类别码：
  R22
• 储存条件：
  存储条件：2-8°C，密封保存，置于干燥处。

制备方法与用途

生物活性

Coumermycin A1 是一种 JAK2 信号激活剂，能够抑制 DNA 旋转酶（DNA Gyrase），从而抑制细菌的细胞分裂。

体外研究

Coumermycin A1 引发的 JAK2 信号激活增加了 SCOS2 的 mRNA 水平，但降低了 leptin 受体的 mRNA 水平。

文献信息

• Methods of treatment for bacterial infections
  申请人：President and Fellows of Harvard College

  公开号：US11191773B2

  公开（公告）日：2021-12-07

  This invention features new compositions and methods that are useful in treating a host with a Gram-negative bacterial infection. Combination therapies comprising an aminocoumarin compound and a polymyxin compound are disclosed, including certain combinations that exhibit synergistic effects. Furthermore, aminocoumarin compounds are described having altered inhibition of DNA gyrase in Gram-negative bacteria and/or the ability to target the transport proteins responsible for assembling lipopolysaccharide in the outer membrane of Gram-negative bacteria.

  本发明的特点是采用了新的组合物和方法，可用于治疗患有革兰氏阴性细菌感染的宿主。本发明公开了由氨基香豆素化合物和多粘菌素化合物组成的组合疗法，包括某些表现出协同效应的组合。此外，还描述了氨基香豆素化合物对革兰氏阴性细菌DNA回旋酶的抑制作用发生改变，和/或能够靶向负责在革兰氏阴性细菌外膜中组装脂多糖的转运蛋白。
• METHODS OF TREATMENT FOR BACTERIAL INFECTIONS
  申请人：President and Fellows of Harvard College

  公开号：US20200163985A1

  公开（公告）日：2020-05-28

  This invention features new compositions and methods that are useful in treating a host with a Gram-negative bacterial infection. Combination therapies comprising an aminocoumarin compound and a polymyxin compound are disclosed, including certain combinations that exhibit synergistic effects. Furthermore, aminocoumarin compounds are described having altered inhibition of DNA gyrase in Gram-negative bacteria and/or the ability to target the transport proteins responsible for assembling lipopolysaccharide in the outer membrane of Gram-negative bacteria.